239 related articles for article (PubMed ID: 31327842)
1. Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene.
Yamazaki M; Nakaseko C; Takeuchi M; Ozawa S; Ishizuka Y; Hatanaka Y; Oshima-Hasegawa N; Muto T; Tsukamoto S; Mitsukawa S; Ohwada C; Takeda Y; Mimura N; Iseki T; Fukazawa M; Sakaida E
Intern Med; 2019 Dec; 58(23):3449-3453. PubMed ID: 31327842
[TBL] [Abstract][Full Text] [Related]
2. Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate.
Zou YS; Hoppman NL; Singh ZN; Sawhney S; Kotiah SD; Baer MR
Cancer Genet; 2017 Apr; 212-213():38-44. PubMed ID: 28449810
[TBL] [Abstract][Full Text] [Related]
3. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
[TBL] [Abstract][Full Text] [Related]
4. [Pediatric myeloid neoplasms associated with eosinophilia and platelet-derived growth factor receptor beta gene rearrangement: a case report and literature review].
Zhang XY; Liu TF; Li CW; Li QH; Zhu XF
Zhonghua Er Ke Za Zhi; 2018 Jan; 56(1):34-38. PubMed ID: 29342995
[No Abstract] [Full Text] [Related]
5. RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib.
Such E; Liquori A; Mora E; Marco-Ayala J; Avetisyan G; Regadera A; Ibañez F; Panadero J; Senent L; Llop M; Díaz A; Vicente A; Luna I; Ibáñez M; Barragán E; Sanz MA; Sanz G; Communidad Valenciana ; Cervera J
Acta Haematol; 2019; 142(2):92-97. PubMed ID: 31085913
[TBL] [Abstract][Full Text] [Related]
6. Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement.
Di Giacomo D; Quintini M; Pierini V; Pellanera F; La Starza R; Gorello P; Matteucci C; Crescenzi B; Fiumara PF; Veltroni M; Borlenghi E; Albano F; Forghieri F; Maccaferri M; Bettelli F; Luppi M; Cuneo A; Rossi G; Mecucci C
Ann Hematol; 2022 Feb; 101(2):297-307. PubMed ID: 34859285
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia.
Xu X; Lu Q; Wang Z; Cai P; Zeng Z; Zhang L; Wang M; Ma L; Ruan C; Chen S
Cancer Res Treat; 2021 Jul; 53(3):889-892. PubMed ID: 33421986
[TBL] [Abstract][Full Text] [Related]
8. Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.
Shimomura Y; Maruoka H; Ishikawa T
Int J Hematol; 2017 May; 105(5):697-701. PubMed ID: 28000100
[TBL] [Abstract][Full Text] [Related]
9. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
[TBL] [Abstract][Full Text] [Related]
10. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
11. [Successful treatment with imatinib for a patient with myeloid neoplasms with eosinophilia and abnormalities of PDGFRB due to t (5;14)(q33;q22)].
Fujii T; Ohno N; Matsui T; Kitahara S; Kobayashi S; Sahara N; Sakamoto N; Matsunaga T
Rinsho Ketsueki; 2021; 62(11):1635-1638. PubMed ID: 34866089
[TBL] [Abstract][Full Text] [Related]
12. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.
Baxter EJ; Kulkarni S; Vizmanos JL; Jaju R; Martinelli G; Testoni N; Hughes G; Salamanchuk Z; Calasanz MJ; Lahortiga I; Pocock CF; Dang R; Fidler C; Wainscoat JS; Boultwood J; Cross NC
Br J Haematol; 2003 Jan; 120(2):251-6. PubMed ID: 12542482
[TBL] [Abstract][Full Text] [Related]
13. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22).
Schwaller J; Anastasiadou E; Cain D; Kutok J; Wojiski S; Williams IR; LaStarza R; Crescenzi B; Sternberg DW; Andreasson P; Schiavo R; Siena S; Mecucci C; Gilliland DG
Blood; 2001 Jun; 97(12):3910-8. PubMed ID: 11389034
[TBL] [Abstract][Full Text] [Related]
14. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
Jawhar M; Naumann N; Schwaab J; Baurmann H; Casper J; Dang TA; Dietze L; Döhner K; Hänel A; Lathan B; Link H; Lotfi S; Maywald O; Mielke S; Müller L; Platzbecker U; Prümmer O; Thomssen H; Töpelt K; Panse J; Vieler T; Hofmann WK; Haferlach T; Haferlach C; Fabarius A; Hochhaus A; Cross NCP; Reiter A; Metzgeroth G
Ann Hematol; 2017 Sep; 96(9):1463-1470. PubMed ID: 28725989
[TBL] [Abstract][Full Text] [Related]
15. A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications.
Gupta SK; Jain N; Tang G; Futreal A; Wang SA; Khoury JD; Yang RK; Fang H; Patel KP; Luthra R; Routbort M; Barkoh BA; Chen W; Mao X; Zhang J; Medeiros LJ; Bueso-Ramos CE; Loghavi S
J Natl Compr Canc Netw; 2020 Oct; 18(10):1300-1304. PubMed ID: 33022638
[TBL] [Abstract][Full Text] [Related]
16. Myeloid Neoplasm with PCM1-PDGFRB Transcript Responded to Low-Dose Imatinib: One Case Report with Literature Review.
Wang Z; Wan L; Lin D; Li CW; Tian Z; Mi YC
Acta Haematol; 2022; 145(5):560-565. PubMed ID: 35340014
[TBL] [Abstract][Full Text] [Related]
17. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.
Vizmanos JL; Novo FJ; Román JP; Baxter EJ; Lahortiga I; Larráyoz MJ; Odero MD; Giraldo P; Calasanz MJ; Cross NC
Cancer Res; 2004 Apr; 64(8):2673-6. PubMed ID: 15087377
[TBL] [Abstract][Full Text] [Related]
18. Myeloid neoplasm with a novel cryptic PDGFRB rearrangement detected by next-generation sequencing.
Zimmermann N; Nassiri M; Zhou J; Miller AM; Zhang S
Cancer Genet; 2020 Jun; 244():55-59. PubMed ID: 32442889
[TBL] [Abstract][Full Text] [Related]
19. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF
Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151
[TBL] [Abstract][Full Text] [Related]
20. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.
Safley AM; Sebastian S; Collins TS; Tirado CA; Stenzel TT; Gong JZ; Goodman BK
Genes Chromosomes Cancer; 2004 May; 40(1):44-50. PubMed ID: 15034867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]